

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATI	ORNEY DOCKET NO.	CONFIRMATION NO.
10/674,268	09/29/2003	Michael Fantuzzi		33503/US	3101
7590 01/07/2005				EXAMINER	
Scott D. Rothe DORSEY & WI	_			KOSSON, ROSANNE	
	perty Department	,		ART UNIT	PAPER NUMBER
50 South Sixth Street, Suite 1500 Minneapolis, MN 55402-1498			_	1651	
			DAT	E MAILED: 01/07/2005	5

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/674,268	FANTUZZI, MICHAEL				
Office Action Summary	Examiner	Art Unit				
	Rosanne Kosson	1651				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period we Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	rely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 29 Se	eptember 2003.					
2a) This action is FINAL . 2b) This	This action is FINAL . 2b) ☐ This action is non-final.					
3) Since this application is in condition for allowan	•					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.				
Disposition of Claims						
4) Claim(s) <u>1-24</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) <u>1-24</u> are subject to restriction and/or e						
Application Papers						
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examiner	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of 	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No d in this National Stage				
Attachment(s)						
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:					

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-10, drawn to a composition comprising coenzyme Q-10 and vitamin E, classified in class 424, subclass 94.1.
- II. Claims 1-9 and 11, drawn to a composition comprising coenzyme Q-10 and a seed oil, classified in class 424, subclass 94.1.
- III. Claims 1-9 and 12, drawn to a composition comprising coenzyme Q-10 and a fish oil, classified in class 424, subclass 94.1.
- IV. Claims 1-9 and 13, drawn to a composition comprising coenzyme Q-10 and an antioxidant, classified in class 424, subclass 94.1.
- V. Claims 14-19 and 22-24, drawn to a soft gelatin capsule comprising coenzyme Q-10 and either rice bran oil or beeswax, classified in class 424, subclass 455.
- VI. Claims 14-18 and 20, drawn to a soft gelatin capsule comprising coenzyme Q-10 and an antioxidant, classified in class 424, subclass 451.
- VII. Claim 21, drawn to a method for delivering an effective amount of coenzyme Q-10, classified in class 424, subclass 94.1.

The inventions are distinct, each from the other because of the following reasons:

The inventions of Groups I-VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different

modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the compositions of Groups I-IV are drawn to various compositions comprising coenzyme Q-10, while the compositions of Groups V and VI are drawn to soft gelatin capsules comprising coenzyme Q-10 and various other components- vitamin E or seed oil or fish oil or an antioxidant or rice bran oil or beeswax. The six groups of products have different components with different properties and, therefore, are used for different purposes, depending on the ingredients required for each use. The compositions of Groups I-IV may be liquids, emulsions or solids other than soft gelatin capsules. Thus, these two compositions clearly have different modes of operation, different functions, and different effects. The search for any one group is not required for the other group, thereby creating an undue burden of search and examination. Thus, restriction for examination purposes is proper.

The invention of Group VII and the inventions of Groups I-VI are related as a process of use and six different products. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the products of Groups I-VI may be used in cosmetics, such as moisturizing creams, or in topical pharmaceutical formulations to treat diseases such as Xeroderma Pigmentosum (see Neigut, US 5,378,461, col. 3, line 55, to col. 4, line 9, and col. 12, line 23, to col. 13, line 5). Thus, the products of Groups I-VI may be used in ways other than in the method of Group VII. Further, the search for

any one group is not required for the other groups, thereby creating an undue burden of search and examination. Thus, restriction for examination purposes is proper.

Further, the different groups have each acquired a separate status in the art, as shown in part by their different classifications.

Because the inventions of Groups I-IV are distinct for the reasons given above, restriction for examination purposes as indicated is clearly proper.

This application contains claims directed to the following patentably distinct species of the claimed invention:

a) each of limonene derivatives listed in claims 4 and 17.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species in a) above for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 3 and 16 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims

are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not

commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rosanne Kosson whose telephone number is 571-272-2923. The examiner can normally be reached on Monday-Friday, 8:30-6:00, with alternate Mondays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Rosanne Kosson Examiner Art Unit 1651

rk 2005-01**-**05

FRANCISCO PRATS
PRIMARY EXAMINER